Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells

Journal of Immunology

Volumn 185, Issue 6, 2010, Pages 3768-3776

  Muraoka, Daisuke ^a,b   Kato, Takuma ^a   Wang, Linan ^a   Maeda, Yuka ^a   Noguchi, Takuro ^a   Harada, Naozumi ^a,b   Takeda, Kazuyoshi ^b   Yagita, Hideo ^b   Guillaume, Philippe ^c   Luescher, Immanuel ^c   Old, Lloyd J ^d   Shiku, Hiroshi ^a   Nishikawa, Hiroyoshi ^a,e  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TESTIS CANCER; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; BIOLISTICS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; FIBROSARCOMA; INJECTIONS, SUBCUTANEOUS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; SARCOMA, EXPERIMENTAL; VACCINES, SUBUNIT;

EID: 78649871196     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903649     Document Type: Article

References (35)

1. Kawakami, Y., and S. A. Rosenberg. 1997. Human tumor antigens recognized by T-cells. Immunol. Res. 16: 313-339.
2. Old, L. J., and Y. T. Chen. 1998. New paths in human cancer serology. J. Exp. Med. 187: 1163-1167.
3. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
4. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
5. Aichele, P., D. Kyburz, P. S. Ohashi, B. Odermatt, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1994. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc. Natl. Acad. Sci. USA 91: 444-448.
6. Aichele, P., K. Brduscha-Riem, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182: 261-266.
7. Toes, R. E., R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156: 3911-3918.
8. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93: 7855-7860.
9. Chen, Y.-T., M. J. Scanlan, U. Sahin, O. Türeci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918.
10. Gnjatic, S., H. Nishikawa, A. A. Jungbluth, A. O. Güre, G. Ritter, E. Jäger, A. Knuth, Y. T. Chen, and L. J. Old. 2006. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95: 1-30.
11. + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA 97: 12198-12203.
12. Le Gal, F. A., M. Ayyoub, V. Dutoit, V. Widmer, E. Jäger, J. C. Cerottini, P. Y. Dietrich, and D. Valmori. 2005. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother. 28: 252-257.
13. + T cell adoptive immunotherapy. Immunity 13: 265-276.
14. Griswold, D. P., and T. H. Corbett. 1975. A colon tumor model for anticancer agent evaluation. Cancer 36(6, Suppl)2441-2444.
15. Nishikawa, H., K. Tanida, H. Ikeda, M. Sakakura, Y. Miyahara, T. Aota, K. Mukai, M. Watanabe, K. Kuribayashi, L. J. Old, and H. Shiku. 2001. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc. Natl. Acad. Sci. USA 98: 14571-14576.
16. Nishikawa, H., E. Sato, G. Briones, L. M. Chen, M. Matsuo, Y. Nagata, G. Ritter, E. Jäger, H. Nomura, S. Kondo, et al. 2006. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Invest. 116: 1946-1954.
17. Kayagaki, N., N. Yamaguchi, F. Nagao, S. Matsuo, H. Maeda, K. Okumura, and H. Yagita. 1997. Polymorphism of murine Fas ligand that affects the biological activity. Proc. Natl. Acad. Sci. USA 94: 3914-3919.
18. Tsushima, F., H. Iwai, N. Otsuki, M. Abe, S. Hirose, T. Yamazaki, H. Akiba, H. Yagita, Y. Takahashi, K. Omura, et al. 2003. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur. J. Immunol. 33: 2773-2782.
19. Ikeda, H., N. Ohta, K. Furukawa, H. Miyazaki, L. Wang, K. Kuribayashi, L. J. Old, and H. Shiku. 1997. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc. Natl. Acad. Sci. USA 94: 6375-6379.
20. Huang, A. Y., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 93: 9730-9735.
21. Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi, S. Fleury, M. Lipp, et al. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410: 106-111.
22. Klinman, D. M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4: 249-258.
23. + T cell numbers, effector function, and antitumor activity. J. Immunol. 182: 7398-7407.
24. Webb, S., C. Morris, and J. Sprent. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63: 1249-1256.
25. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746.
26. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
27. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
28. + T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202.
29. Fife, B. T., and J. A. Bluestone. 2008. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224: 166-182.
30. + T cell expansion in melanoma patients. J. Immunol. 182: 5240-5249.
31. Krueger, A., S. C. Fas, S. Baumann, and P. H. Krammer. 2003. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol. Rev. 193: 58-69.
32. Xu, X. N., M. A. Purbhoo, N. Chen, J. Mongkolsapaya, J. H. Cox, U. C. Meier, S. Tafuro, P. R. Dunbar, A. K. Sewell, C. S. Hourigan, et al. 2001. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using α3 domain mutants of MHC class I/peptide complex. Immunity 14: 591-602.
33. + T-cell cytotoxicity. Cancer Res. 69: 6615-6623.
34. Keir, M. E., M. J. Butte, G. J. Freeman, and A. H. Sharpe. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704.
35. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10: 29-37.